External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Archive

Access the archives to find the information you want

No results found

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
This presentation describes the results of an interim analysis of treatment-naïve patients (baseline to month 6) receiving faricimab▼ in the innovative real-world VOYAGER study. The global VOYAGER study investigates the real-world effectiveness, safety, treatment patterns and anatomical features affecting vision outcomes with faricimab▼ in patients with nAMD and DME on a global level. Treatment-naive eyes achieved visual gains and anatomic improvements during the follow-up period.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Real-World Effectiveness of Faricimab▼ in Patients with Diabetic Macular Edema: 12-Month Outcomes from FARETINA-DME and FARWIDE-DME Studies
This presentation summarizes the real-world efficacy and safety of faricimab▼ from the real-world FARETINA and FARWIDE studies in patients with treatment naïve DME. The findings demonstrated that real-world faricimab▼ use is effective in improving visual acuity and decreasing CST with acceptable tolerability in patients with DME. Additionally, treatment with faricimab▼ is durable with fewer injections required after 6 months suggesting interval extensions.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries, a subtype of nAMD which is highly prevalent in Asia and a population underrepresented in the phase 3 TENAYA/LUCERNE trials. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Response of Large or Serous Pigment Epithelial Detachment to Faricimab▼ versus Aflibercept in Patients with Neovascular Age-related Macular Degeneration: A Subgroup Analysis from TENAYA and LUCERNE
This presentation summarizes the efficacy of faricimab▼ in improving Pigment Epithelial Detachment (PED) outcomes in patients with nAMD from the TENAYA and LUCERNE trials. This subgroup analysis demonstrates that faricimab▼ results in greater and faster reductions in maximum PED thickness compared with aflibercept.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Real-World Effectiveness of Faricimab▼ in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Outcomes from the FARETINA-nAMD and FARWIDE-nAMD Studies
This presentation summarizes key clinical outcomes from the real-world FARETINA and FARWIDE studies in patients with treatment-naïve nAMD, demonstrating that real-world faricimab▼ use is effective in improving visual acuity and decreasing CST with acceptable tolerability in patients with nAMD. Additionally, treatment with faricimab▼ is durable with fewer injections required after 6 months suggesting interval extensions.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 19 / Roche
Genomics Annotation and Interpretation in Somatic Oncology with a Highly Structured Data Model
navify® Mutation Profiler provides an automated cloud-based solution to streamline the process of annotating, interpreting and reporting variants from next-generation sequencing (NGS) somatic oncology test results. Ephesus is an internal web application enabling expert curation for construction of a robust knowledgebase of NGS biomarkers to support the mutation profiler. In this study, we assessed the reporting capability of Ephesus/navify Mutation profiler by querying somatic variants in ~170K real cancer cases from the AACR GENIE® (v16.1) project, and comparing against several public knowledgebases. Ephesus/navify Mutation Profiler outperformed the other knowledgebases in having the highest number of interpreted cases and biomarker profiles.